Eli Lilly, Stock

Is Eli Lilly Stock a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.
Eli Lilly & Co. stock underperforms Friday when compared to competitors
Shares of Eli Lilly & Co. LLY slid 4.73% to $869.58 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.55% to 5,770.20 and the Dow Jones Industrial Average DJIA rising 0.52% to 42,801.72.
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?
Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from a late-stage study on next-generation obesity drug, CagriSema. Top-line data from the phase III REDEFINE 2 study on Novo Nordisk’s CagriSema showed that treatment with the drug led to a weight loss of 15.
Why Eli Lilly Stock Flopped Today
Zeroing in on Eli Lilly, the company is already well established with Zepbound, which should continue to sell briskly as the world waits for a more powerful and efficacious obesity drug to hit the market. Besides, the American pharmaceutical king has many other products currently on pharmacy shelves, and a wide and active pipeline.
Eli Lilly (NYSE:LLY) Surges 5% Following Breakthrough BRAVE-AA-PEDS Study Results
Recent developments at Eli Lilly (NYSE:LLY) have highlighted significant strides in both product innovation and operational ...
STAT1d
Eli Lilly’s Dave Ricks takes home $114 million as obesity drugs fuel company’s fortunes
Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.
Eli Lilly plans to launch weight-loss drug in emerging markets this year
Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...
RiverBender.com1d
Durbin, Warren, Welch, Sanders Demand Answers From Telehealth Companies Regarding Their Financial Relationship With Pfizer, Eli Lilly Amid Concerns
WASHINGTON, D.C. U.S. Senate Democratic Whip Dick Durbin (D-IL) sent letters to five telehealth companies that have held ...
Fierce Pharma3d
With Eli Lilly flying high, CEO David Ricks collects 10% pay bump to $29.2M
Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...
Unpacking the Latest Options Trading Trends in Eli Lilly
Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...
Eli Lilly (LLY) Slid on Rare Revenue Miss in its 3Q Update
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...
Yahoo Finance2d
Eli Lilly and Company (LLY)
Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily ...
Eli Lilly plans launch of weight-loss drug in emerging markets in 2025, CFO says
Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and ...
Is Eli Lilly and Company (LLY) the Best Pharma Stock to Buy According to Hedge Funds?
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...